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Introduction
Autoimmune hepatitis (AIH) is a rare, chronic progressive immune-mediated inflammatory disorder of the liver that affects children and adults. 1, 2 It is characterized by female predominance, hypergammaglobulinaemia, circulating autoantibodies and interface hepatitis on liver biopsy. 1 Clinical presentation ranges from asymptomatic biochemical liver abnormalities to acute liver failure or cirrhosis. 1, 3, 4 Genetic factors play a role in the natural history of AIH; white HLA-DRB1*0301 positive AIH type 1 patients are more likely to be male and to deteriorate despite steroids and HLA-DRB1*0401 positive patients tend to be older and respond better to corticosteroid therapy. [5] [6] [7] A few studies reported differences in disease presentation and outcome between different ethnic groups. [8] [9] [10] [11] [12] In two studies from the USA and the UK it was found that non-Caucasian patients with AIH have more aggressive disease at initial presentation, a higher likelihood of cirrhosis being present at diagnosis. 9, 10 A recent population based analysis found that black AIH patients have a higher rate of hospitalisation and death during hospitalisation than white patients. 13 The difference in presentation and outcome between black and non-black patients may in part be genetically driven, 14, 15 but confounding structural and social factors such as socioeconomic status and access to health care have not convincingly been excluded. The studies to date have been single centre experiences reporting outcomes with relatively small numbers of patients. We aimed to compare the clinical presentation and outcome of black AIH patients from African or Caribbean descent in reference to a Caucasian population in a retrospective multicentre study. 
Methods
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reviewed. The King's College Hospital and the Royal Free Hospital are 2 of 7 liver transplant centres in the UK. These liver units treat local patients, but both have large national and international referral practices. 16 The DAIHG cohort data was updated in 6 academic centres, including all 3 Dutch transplant centres, and 10 general referral hospitals. 17 Patient records were systematically reviewed and examined with regards to self-reported racial background as well as clinical characteristics, excluding patients with features of primary sclerosing cholangitis and primary biliary cholangitis variant syndromes. Black background was based on self-reported sub-Saharan Africa, Afro-American or Afro-Caribbean origin, whereas white background was based on self-reported Caucasian or European origin. In the cohort of 985 patients, black race was identified in 88 patients and white race in 897 ( Figure   1 ). All patients had a clinical diagnosis of probable or definite AIH according to the 1999 IAIHG scoring system (564 UK and 421 Dutch AIH patients). We compared the black and white patient groups in relation to clinical, laboratory and histological features as well as treatment outcome, liver transplantation and overall and liver-related mortality.
As described in previous studies, standard diagnostic criteria for the presence of AIH were fulfilled. 17, 18 All patients were treated according to standardized protocols published previously. 19, 20 Response to treatment and relapse were defined in accordance with the revised IAIHG criteria. 21 Second-line therapy was defined as ever being treated with medications other than azathioprine or corticosteroids (including mycophenolate mofetil, tacrolimus, cyclosporine A or sirolimus). The presence of concomitant extra-hepatic autoimmune disease including celiac disease, autoimmune thyroiditis as well as systemic lupus erythematosus (SLE) was retrieved from the patient records. Data on mortality and causes of death were retrieved from medical records and/or by contacting the attending physicians or general practitioners/family doctors. In the Dutch cohort, liver transplantation rates were assessed by cross-checking the clinical record data with the transplantation list from all three transplantation centers. Follow-up ended at the date of death or liver transplantation, or at the end of the study. This study was approved by the Research Ethics M A N U S C R I P T
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Results
UK-cohort
The UK cohort consisted of 68 black patients (12%) and 496 white patients (88% and 38 white patients (8%) underwent liver transplantation (P=0.007). Sixteen black patients (24%) and 67 white patients (14%) reached the combined end-point of liver-transplantation and liver-related death (P=0.029).
Netherlands cohort
The Netherlands cohort consisted of 20 black patients (5%) and 401 white patients (95%).
Black patients presented at a younger age (median 38 vs 46 years, P=0.05), but the No black patients and 11 white patients (3%) underwent liver transplantation (P=1.0). Three black patients (15%) and 33 white patients (8%) reached the combined end-point of livertransplantation and liver-related death (P=0.2).
Combined cohort
The combined study population comprised of 985 patients (736 definite AIH and 259 probable AIH, black: n=88, white n=897). Black patients presented at a younger age than white patients (median 38 vs 45 years, P=0.007), but had similar gender distribution and IAIHG post-treatment scores as well as auto-antibody positivity (Table 1) . Black patients had higher IgG levels (mean 31.0 vs 27.5 g/L, P=0.04) and they had a higher rate of SLE (10% vs 2%, P<0.001). There were no differences in age or severity of presentation between black Both black and white patients were treated with steroids as standard induction therapy (99% vs 95%, P=0.2) and had a similar exposure to azathioprine as maintenance therapy (75% vs 81 %, P=0.2; Table 2 ). Black patients had a similar clinical response rates to standard therapy compared to white patients (86 % vs 91 %, P=0.2) and also comparable occurrence of at least one relapse (57% vs 50% P=0.3). However, during follow-up there was a higher proportion total number of recorded relapses in black AIH patients in both the King's College
Hospital and the Dutch cohorts (P=0.018). Overall, there was no significant difference in the rate of use of second-line therapies (17% vs 11%, P=0.1).
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Outcome
The median duration of follow-up in the combined cohort was shorter in the black than in the of hepatocellular carcinoma (HCC) development was similar in both groups (2% vs 2%, P = 1.0), but the incidence per 10 patient years was lower in the white patient group (0.018/10 patient years vs 0.022/10 patient years). The rate of transplantation and liver related death was significantly higher in the black patients in the UK cohort (P = 0.029), whereas the rates of transplantation, liver-related mortality and overall mortality did not differ significantly between black and white patients in the Dutch cohort. In the combined cohort the black AIH patients underwent liver transplantation more often than white patients (14% vs 6% respectively, P=0.002), but overall mortality was similar between the two groups (11% vs 15%, P=0.3). Log-rank survival analysis showed an impaired combined transplant-free and liver-related mortality for black patients in the combined UK and Dutch cohorts (P<0.001, Figure 2A ). This was primarily driven by the UK cohort (P<0.001, Figure 2B -C) as the Dutch cohort did not reveal a significant association (P=0.4, Figure 2D ). This suggest that the 
Discussion
In this retrospective study of black patients with AIH from selected centres in the UK and Netherlands we observed a lower age of onset and a greater risk of liver transplant or liver related death, which may illustrate a more aggressive disease course compared to white M A N U S C R I P T
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patients. We also demonstrated that these outcomes occurred in healthcare systems with universal access to care, even without a higher likelihood of cirrhosis at diagnosis or without an initial inferior apparent treatment responses to induction therapy among black patients.
Higher IgG levels at diagnosis were noted compared to a white reference population.
Although no differences in terms of autoantibody profile were noted, black patients more often had concomitant SLE. Overall, there was a low rate of HCC and we did not observe an association between HCC development and race which is consistent with the similar rates of cirrhosis in both groups. 22 In both countries and healthcare systems, the vast majority of patients received corticosteroids for induction of remission, with azathioprine being added for maintenance therapy. Interestingly, there were no differences in terms of response of therapy between groups, and a similar proportion of patients needed escalation of therapy with second line agents. However, the number of relapses were higher in black patients compared to white patients, suggesting that these patients have a more severe disease phenotype and are in need of a better maintenance therapy. Alternatively, limited compliance to therapy could be factor, although we could not reliably address this issue. Lim et al. reported that although both black and white patients responded well to standard therapy, the dosage of steroids was significantly higher in black patients despite similar use of azathioprine (Table 4. ). 8 These data suggest that current treatment regimens may be inadequate for black patients, and therefore future studies should focus on the development of different treatment protocols stratified according to race to address this issue. 23, 24 Importantly, this study also confirms that race also impacts on the natural history of the disease, since black patients were more likely to have progressive disease requiring liver transplantation. We propose three possible explanations for this outcome. Firstly, and although this was a multicentre study, it was hospital based and therefore could be limited by tertiary referral bias, which might lead to an overestimation in severity. In line with this, we observed overall less severe disease with lower rates of cirrhosis and outcomes in the Dutch cohort, which comprised AIH patients managed predominantly at general, academic, and less frequently at transplant hospitals, whereas the UK cohort consisted of two transplant M A N U S C R I P T
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centres. Nevertheless, as advanced health care is accessible through both the National Health Service in the UK and mandatory insurance policy in the Netherlands, this bias likely affects both groups. Hence it seems unlikely to account for the poorer outcome observed in black AIH patients, although the relatively small number of included black AIH patients in the Dutch cohort may explain the lack of association with outcome in the Dutch cohort due to lack of power. A recent study of the UK and USA national liver transplant registries reported that black patients were listed at younger age and had higher model for end-stage liver disease (MELD) scores than other races (Table 4. ). 25 Secondly, socioeconomic status, healthcare access and practice, and thus quality of care are factors that must be considered comparing disease characteristics and outcomes amongst different groups. 26 For example, mortality differences between white and African descendent North Americans with cirrhosis disappear after adjustment for socio-economic status. 27 The earlier age at diagnosis and similar cirrhosis rates argue against a systematic delay in the diagnosis of AIH in black patients, assuming that untreated disease progression rates are similar. The elevated hazard of liver transplantation or liver related death for black patients could be attributed to a more aggressive disease phenotype, which might progress despite similar rates of initial treatment response, which is supported by a recent population study in the USA (Table 4) . and with a lower frequency of cirrhosis and need for liver transplantation. 5 Interestingly, it has been shown that HLA-DR4 is under-represented in African Americans compared to Caucasian individuals. 31 The current study provides no information about HLA class II genotypes, constituting one key limitation in interpreting the data. Additionally, common with other retrospective studies, our results may be influenced by referral bias, missing data, skewed outcome parameters and we cannot ascribe causality of poorer outcomes to race.
As race was self-reported and categorised as black or white, we could not control for the likely genetic heterogeneity within these large groups. A further limitation is the lack of data on adherence to treatment within the studied groups. However, the strength of this study comprises the large catchment area in two different countries with accessible healthcare systems.
Future, prospective studies are required to explore the mechanism, importance and generalizability of our findings. The impact of genetic variants amongst different racial groups in Europe, and globally, upon clinical outcomes would help inform our understanding of disease biology, aetiology and risk prediction. Qualitative and quantitative exploration of the experiences of patients and access to healthcare, capturing data on, amongst others, socio-economic status, race, gender and treatment centre should be performed. The proposed IAIHG retrospective and prospective registries offer a suitable starting point and further focused studies will be required. 23, 24 In summary, the results of this study show that the presentation and clinical course of AIH is different in black patients compared to a reference cohort of white AIH patients. Black AIH patients present at a younger age, with higher IgG levels and a higher prevalence of SLE than a white reference population. Black AIH patients appear to have a higher rate of transplantation and liver-related mortality, despite a similar disease stage at presentation. It M A N U S C R I P T
is likely that a combination of different factors may account for this observation, including time of diagnosis, treatment regimen, and genetic and environmental disparities between the different groups.
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What You Need to Know Background -Autoimmune hepatitis is a chronic inflammatory condition of the liver, that can manifest in all ethnic and racial groups -Genetics, ethnicity and race have an impact on the development of immune mediated conditions -Socioeconomic status may affect healthcare outcomes Findings -Autoimmune hepatitis patients of black background present at an earlier age than white patients -Black autoimmune hepatitis patients have a more severe disease course, with a higher chance of liver transplantation or death due to liver failure Implications for patient care -Black autoimmune hepatitis patients may need a more stringent therapeutic approach in order to prevent worse liver-related outcomes.
